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AUT00063 is an experimental new medicine that has been demonstrated to suppress spontaneous hy-
peractivity by modulating the action of voltage-gated potassium-channels in central auditory cortical
neurons of a rodent model. This neurobiological property makes it a good candidate for treating the
central component of subjective tinnitus but this has not yet been tested in humans. The main purpose of
the QUIET-1 (QUest In Eliminating Tinnitus) trial was to examine the effect of AUT00063 on the severity
of tinnitus symptoms in people with subjective tinnitus. The trial was a randomised, placebo-controlled,
observer, physician and participant blinded multi-centre superiority trial with two parallel groups and a
primary endpoint of functional impact on tinnitus 28 days after the ﬁrst drug dosing day.
The trial design overcame the scale and logistical challenges of delivering a scientiﬁcally robust, sta-
tistically powered multi-centre study for subjective tinnitus within the National Health Service in En-
gland. The trial was terminated early for futility. Overall, 212 participants consented across 18 sites with
91 participants randomised to groups using age, gender, tinnitus symptom severity and hearing status as
minimisation factors. While the pharmacokinetic markers conﬁrm the uptake of AUT00063 in the body,
within the expected therapeutic range, with respect to clinical beneﬁt ﬁndings indicated that AUT00063
was not effective in alleviating tinnitus symptoms (1.56 point change in Tinnitus Functional Index). In
terms of clinical harms, results indicated that a daily dose of 800mg capsules of AUT00063 taken for 28
days was safe and well tolerated. These ﬁndings provide signiﬁcant advances in the drug development
ﬁeld for hearing sciences, but raise questions about the predictive validity of certain rodent models of
noise-induced hearing loss and tinnitus, as least for the mechanism evaluated in the present study. Trial
Registration: (EudraCT) 2014-002179-27; NCT02315508.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).n of Clinical Neuroscience,
gham, NG7 2UH, UK.
(D.A. Hall), jaydip.ray@sth.
alice.sharman@autifony.com
ison), peter.harris@autifony.
(M. Daniel), bonnie.millar@
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B.V. This is an open access article u1. Introduction
Tinnitus is a commonmedical symptom that can be debilitating.
Tinnitus affects between 5% and 43% of the general population
depending on the deﬁnition of tinnitus, and prevalence increases
with age (McCormack et al., 2016). For many people, tinnitus is
persistent and troublesome, and has disabling effects such as sleep
difﬁculties, problems concentrating, impaired communication and
social interaction, low mood including generalised anxiety andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Abbreviations
ABR Auditory Brainstem Response
AE Adverse Event
ANCOVA Analysis of Covariance
CI Conﬁdence Interval
ECG Electrocardiogram
eCRF electronic Case Report Form
EEG Electroencephalography
IDMC Independent Data Monitoring Committee
MHRA Medicines and Healthcare products Regulatory
Agency
NHS National Health Service
NRES National Research Ethics Service
QTc corrected Q-T interval
SAE Serious Adverse Event
SD standard deviation
TFI Tinnitus Functional Index
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Themost prevalent form of the condition is subjective tinnitus, a
condition inwhich the experience of an auditory sensation is of the
individual alone. Risk factors for developing subjective tinnitus
include noise exposure, hearing loss, ototoxic medication, and head
injury (e.g. Baguley et al., 2013). Because otological conditions,
especially high-frequency sensorineural hearing loss, present one
of the major risk factors for tinnitus, the condition is often deemed
to reﬂect neural changes in the central auditory system in response
to cochlear damage (Eggermont and Roberts, 2015). Indeed, sub-
jective tinnitus is generally considered to have a central nervous
system component. While the trigger for tinnitus is thought to
occur at the peripheral level, a cascade of neuro-plastic events
throughout the central auditory pathway develops and sustains the
symptoms. Hence, preventing or treating sensorineural hearing
impairment could be more successful in avoiding or delaying
tinnitus than current intervention approaches which merely help
people to manage their existing tinnitus symptoms (Nore~na, 2011).
The clinical rationale for the study is therefore motivated by the
absence of a singularly effective treatment for subjective tinnitus
which either alleviates the reactions to the tinnitus or which re-
duces the tinnitus percept (e.g. Baguley et al., 2013). Cognitive
behaviour therapy delivered by qualiﬁed psychologists (Martinez-
Devesa et al., 2010), and sound therapies such as ampliﬁcation
devices and sound generators (Sereda et al., 2018) may have limited
beneﬁt for some people. But there are currently no approved
pharmaceutical treatments for tinnitus, even though surveys sug-
gest that people would prefer a pill to reduce or eliminate their
tinnitus percept (Tyler, 2012). A survey across General Practitioners
and Ear, Nose and Throat specialists in six countries (US, Germany,
UK, France, Italy and Spain) indicated a broad range of off-label
pharmacological prescriptions to treat conditions associated with
subjective tinnitus including anti-vertigo products and cortico-
steriods, with antidepressants and sedatives being particularly
common when the condition has lasted 3 months (Hall et al.,
2011). Respondents were generally dissatisﬁed with current drug
treatments; noting their lack of speciﬁcity for tinnitus and general
ineffectiveness. Given the urgent need for a targeted drug treat-
ment for tinnitus, it is perhaps surprising that there are so few
research programmes in the pipeline (Langguth et al., 2019).
However, this simply reﬂects the historical absence of a clear un-
derstanding of the disorder. While there have been signiﬁcant ad-
vances in understanding tinnitus mechanisms over the past fewdecades, there have been nomajor breakthroughs in the theoretical
understanding and availability of preclinical tools necessary to
conduct a robust drug development programme for the central
auditory system. It is important to note that there is no cumulative
evidence from relevant studies to draw upon. Pharmacology trials
in hearing are “pretty much white space” (Jarvis, 2014).
Noise exposure damages the cochlea, triggering hearing loss in
animals and humans and provoking neural degeneration in pe-
ripheral and central auditory structures. Neuronal excitability is
one of the known consequences of noise damage over the short
term, and this is a potential neural correlate of tinnitus (Eggermont,
2013; Eggermont and Roberts, 2015; Pilati et al., 2012a; Roberts
et al., 2010). In general, voltage-gated potassium channels play a
major role in determining intrinsic cellular excitability. The Kv3
family of such channels play a role in shaping the action potential
and ﬁring properties. In a rat model, noise exposure has been
shown to down-regulate high voltage activated potassium currents
that are likely responsible for the high-frequency burst ﬁring of
neurons characteristic of spontaneous hyperactivity (Pilati et al.,
2012b). In particular, Kv3.1 is a candidate neurobiological target
for developing drug treatments for tinnitus because it is a high-
threshold potassium channel that is expressed in the cell mem-
brane of fast-spiking neurons throughout the central auditory
system (Chambers et al., 2017).
AUT00063 is a novel centrally acting drug developed as a potent
and selective modulator of Kv3.1 and Kv3.2 voltage-gated potas-
sium channels, shifting their voltage-dependence of activation to-
wards more negative potentials (Anderson et al., 2018). AUT00063
has been demonstrated to suppress spontaneous hyperactivity
induced by noise exposure in dorsal cochlear nucleus fusiform cells
in a hamster model (Glait et al., 2018), and in multi-unit activity
recorded in the inferior colliculus in a mouse model (Anderson
et al., 2018). Based on this evidence, the authors set out to inves-
tigate whether modulation of Kv3 channels in the auditory brain-
stem andmidbrain could provide symptomatic relief in peoplewith
tinnitus associated with noise exposure. AUT00063 is the ﬁrst drug
developed to target the central (‘neural’) component of tinnitus
associated with the perception of tinnitus.
The present phase IIa trial followed a ﬁrst-in-human, phase I
double-blind, randomised, single and repeat dose escalating trial in
healthy young (18e45 year old) men and older men and women
(aged 60e75 years) designed to assess safety, tolerability, and
pharmacokinetics of AUT00063 following oral doses. Based on the
Phase I trial data, side effects wereminor, mostly mild in nature and
the most frequent were headache, fatigue, tiredness, abdominal
pain and toothache (Autifony Therapeutics Ltd, unpublished re-
sults). Most of these side effects resolved spontaneously. Based on
the pharmacokinetic data from the volunteers, it was concluded
that 800mg administered daily would result in plasma concen-
trations within the therapeutic range for tinnitus. The half-life was
found to be in the region of three days, and hence steady state
concentrations were achieved between 1 and 2 weeks following
continuous dosing.
The primary objective of the phase IIa trial was to compare the
effect of 28 days repeat dosing with AUT00063 on the functional
impact of tinnitus in adults with subjective tinnitus associated with
noise and/or age-related sensorineural hearing loss, relative to a
placebo. A secondary efﬁcacy objective was to compare AUT00063
and placebo groups after 28 days on tinnitus loudness. As is
customary in an early stage clinical trial, safety and tolerability of
AUT00063 were also important secondary endpoints. Three
exploratory objectives compared repeat administration of
AUT00063 and placebo on: i) within-subject changes in the func-
tional impact of tinnitus and tinnitus loudness,
ii) the effect of AUT00063 on a pharmacokinetic marker (i.e.
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discrete outcome domains associated with the functional impact of
tinnitus (intrusiveness, sense of control, cognitive interference,
sleep disturbance, auditory difﬁculties attributed to tinnitus,
relaxation, tinnitus-speciﬁc ‘quality of life’ and emotional distress),
and iv) individual patterns of clinically meaningful improvement or
worsening of the clinical impact of tinnitus. All objectives
(including exploratory objectives) were pre-deﬁned in the study
protocol.
2. Material and methods
2.1. Trial design
As a short-form name, the trial was called QUIET-1 (QUest In
Eliminating Tinnitus). This was a randomised, placebo-controlled,
multi-centre superiority trial with two parallel groups and a pri-
mary endpoint of the functional impact on tinnitus 28 days after
the ﬁrst drug dosing day. This trial was designed to demonstrate
superiority of AUT00063 (800mg once daily) over placebo. Staff
collecting outcome data (observer), physicians and participants
were blinded to treatment allocation (triple-blinded design).
Stratiﬁed randomisation used age, gender, tinnitus symptom
severity and hearing status as minimisation factors, with a 1:1
treatment allocation. Our reporting of QUIET-1 follows the rigorous
standards deﬁned in the Consolidated Standards of Reporting Trials
(CONSORT) Statement (Schulz et al., 2010).
The protocol was independently reviewed and approved by the
National Research Ethics Service (NRES) Committee Yorkshire and
the Humber e Leeds East (Ref: 14/YH/1090) and the Medicines and
Healthcare products Regulatory Agency (MHRA) (Eudract number:
2014-002179-27). The trial Sponsor was the Autifony Therapeutics
Ltd (Stevenage, UK). The trial was registered on ClinicalTrials.gov on
09 December 2014 (Identiﬁer: NCT02315508) and the results
were published on the EU clinical trials register (www.
clinicaltrialsregister.eu) on 08 Dec 2016 (EudraCT: 2014-002179-27).
2.2. Participants
A diverse range of methods, continuous monitoring, mitigation
strategy and adequate resourcing were essential for achieving the
recruitment rate required by the QUIET-1 protocol (Sanchez et al.,
2018). Participant recruitment was primarily from direct referral
to those National Health Service (NHS) organisations approved for
recruitment and by posters displayed in public areas in those local
hospitals. Additionally, the trial team placed a series of features in
several national newspapers, hearing-related magazines (for the
public and hearing healthcare professionals), and hearing charity
websites. Some recruiting sites advertised through NHS general
practitioner centres or engaged in additional regional advertising in
newspapers and magazines and interviews on local radio stations,
following ethical review and approval.
Table 1 provides details of inclusion and exclusion criteria for
the trial according to the ﬁnal version of the Clinical Trial Protocol
(version 1.5). We sought to identify subjective tinnitus with
noticeable tinnitus symptoms that had existed for not less than 6
months, and not more than 18months at study start and within a
deﬁned range of sensorineural hearing loss. These eligibility criteria
were based on discussion with Sponsor and audiologist experts.
There is no widespread standard for grading the temporal charac-
teristics of tinnitus, but many clinical studies use 6 months as a
benchmark for deﬁning the boundary between acute and chronic
tinnitus. Tinnitus experienced for >18 months can be considered as
a long-standing tinnitus which may involve psychological or other
mechanisms responsible for maintaining some of the symptomsand which differ from those mechanisms responsible for its initial
generation. A score 24 and 68 on the TFI was informed by the
best available evidence at the time which was an estimate of the
interquartile range on the TFI using UK-based data on the target
population (Fackrell et al., 2018; ClinicalTrials.gov Identiﬁer:
NCT01541969).
Four sets of substantial amendments were submitted and
approved by the NRES and MHRA, and all changes relevant to the
eligibility criteria are reported. The trial team operated a central
telephone number where those interested could ﬁnd out if they
met the basic entry criteria. Individuals answered a scripted pre-
screening interview with general questions on tinnitus character-
istics, otological comorbidities and general health. This was not part
of the formal trial assessment as no personal details were taken.
Those passing the screen were simply advised to contact their
nearest recruiting site.
Participants were involved in the trial for up to 10 weeks from
start to ﬁnish and the schedule of clinical research activities is
illustrated in Fig. 1. These comprised 4 or 5 visits to the clinic plus a
5e10-min telephone call at the mid-way point. In brief, a 2e3 h
initial screening visit included informed consent followed by
medical and audiometric assessments required for determining
eligibility. This could take place at any time up to 28 days before
dosing. The second visit was a 1-1 ½ hour training baseline which
was intended to expose participants to the loudness matching
procedure and to administer a structured interview for estimating
lifetime noise exposure. At the discretion of the trial team, these
assessments could be carried out on the same day as screening. The
(third) visit repeated some of the medical and audiological as-
sessments and took 4-4 ½ hours. This visit is called ‘Day 1’ (D1)
because it corresponds to the ﬁrst dose which was taken under
clinical supervision. Participants at the Nottingham site undertook
additional assessments of pharmacological electroencephalog-
raphy (pharmacoEEG) and Auditory Brainstem Response (ABR)
activity, extending the D1 visit from 4 h up to 11 h including a wait
of approximately 6 h in between pre- and post-dose measures.
These were optional. The last day of dosing (Day 28, D28) was the
study end point (visit 4). This 2e3 h visit entailed repeat medical
and audiological assessments. And again, for participants at the
Nottingham site optional assessments of pharmacoEEG and ABR
activity extended this visit up to 5 h. The main purpose of the ﬁnal
visit (visit 5) at Day 42 (D42) was to enable medical assessments for
the safety analysis. This took about 1 ½ hours.
Participants received a ﬁnancial compensation for loss of
working hours and/or inconvenience. In addition, travel and/or
meal expenses were reimbursed for each visit.
2.3. Study settings
The trial took place across 18 NHS organisations. Recruitment
was open from 23 October 2014 to 08 October 2015, but the
opening of sites was staggered over this period and this is fully
reported in Table 2. The ﬁrst 10 sites were opened by January 2015
and the additional 8 sites were opened through April to July 2015 to
support slower than expected recruitment. Three of the additional
sites opened did not screen any participants as the trial was
terminated early for futility.
2.4. Intervention
AUT00063 was formulated for oral administration in Swedish
Orange, hard gelatin (size 0) capsules containing white to slightly
coloured powder that included 200mg of AUT00063 as the parent
compound along with the following excipients: sodium lauryl
Table 1
Inclusion and exclusion criteria assessed during the telephone pre-screening and screening visit (visit 1) according to the ﬁnal version of the Clinical Trial Protocol (version 1.5).
Four sets of substantial amendments were submitted and approved by the NRES and MHRA and all changes relevant to the eligibility criteria are given in column 2.
Eligibility criteria History of substantial changes to the Clinical Trial Protocol
Inclusion criteria (Clinical Trial Protocol v1.5, dated 2 July 2015)
1. English speaking male or female, 18 years of age, UK residents, registered with a UK General
Practitioner
2. Stable tinnitus (consistent from day to day), score 24 and 68 on the Tinnitus Functional Index
3. Duration of noticeable tinnitus symptoms 6 months and 18months at enrolment
4a. Pure Tone Average (for frequencies at 0.5, 1, 2, and 4 kHz) 60 dB Hearing Level (HL), across the two
ears
v1.3 (13 Nov 2014) amended to include¼ 20 and¼ 60 dB HL
in the Pure Tone Average calculation.
v1.4 (9 Feb 2015) requirement for Pure Tone
Average 20 dB removed
4b. Any single frequency at 0.5, 1, 2, 4, 6 or 8 kHz with an audiometric threshold estimate >20 dB to v1.4 (9 Feb 2015) individual frequency thresholds >20 dB
instead of lower Pure Tone Average 20 dB
4c. If a hearing aid or sound generator user then conﬁrmed consistent daily device usage over the past
six months
5. Normal life expectancy for age, based on physician's judgement.
6. Females of child-bearing potential must have a negative pregnancy test at screening and baseline
visits, and practice two reliable methods of contraception throughout the study.
v1.1 (14 Aug 2014) amended to ensure that women use two
methods of contraception
7. Able to understand and comply with the requirements of the study and signed Informed Consent
Form.
Exclusion criteria (Clinical Trial Protocol v1.5, dated 2 July 2015)
1. History of hypersensitivity or idiosyncratic reaction to any component of the test medication
2. Any acute disabling tinnitus
3. Diabetes mellitus with an HbA1C>8% (64mmol/mol) to allow the inclusion of patients with well
controlled Type 2 diabetes
4. Previous cardiac rhythm disorders or ECG rhythm abnormalities whether symptomatic or not, and
considered to be clinically signiﬁcant
s
5. Severe hearing impairment such that oral-only communication is unreliable
6. History of important cardiac, endocrine, pulmonary, neurologic, psychiatric, hepatic, renal,
hematologic, immunologic, or other major diseases deemed clinically signiﬁcant at the time of the
study which might be jeopardised by entering the study
7. Moderate or severe depression or generalised anxiety as indicated by a score of 11 out of 21 on the
Hospital Anxiety and Depression Scale (Zigmond and Snaith, 1983)
8. Alcohol or drug abuse deemed clinically signiﬁcant, based on physician's judgement.
9. History of poor cooperation, non-compliance with medical treatment, or unreliability, based on
physician's judgement.
10. Participation in any clinical research study evaluating another investigational drug or therapy within
30 days or at least 5 half-lives (whichever is longer)
11. Participation in a hearing study, involving an intervention, within 3 months from the last study visit
12. Use of central nervous system active drugs except analgesics and those speciﬁed in the Clinical Trial
Protocol
13. Non-study treatments for the management of tinnitus, severe insomnia, major depressive disorder,
severe anxiety, or post-traumatic stress disorder. (Counselling is allowed as long as it was
implemented prior to screening).
14. Central nervous system pathologies (such as Multiple Sclerosis, Parkinson's disease etc).
15. Tinnitus as a concomitant symptoms of a known otological condition (including but not limited to
otitis externa, otitis media, otosclerosis, cholesteatoma, Meniere's disease, or other vestibular
problems, acoustic neuroma, or temporo-mandibular joint disorder)
16. Pulsatile tinnitus (rhythmical sounds that often beat in time with the heartbeat)
17. Intermittent tinnitus (comes and goes from one day to the next), based on physician's judgement.
18. Surgical or medical condition that would be expected to signiﬁcantly affect absorption of medicines v1.3 (13 Nov 2014) amended to include only those surgeries
or medical conditions expected to affect absorption
19. Presence or history of relevant severe adverse reaction to any drug or a history of sensitivity to
potassium channel modulators
20. Blood pressure and heart rate (in seated position) outside the clinically relevant ranges speciﬁed
21. From the electrocardiogram representation of ventricular depolarization and repolarisation, a
corrected QT interval <330ms in males or <340ms in females or >450ms for bothmales and females
v1.1 (14 Aug 2014) amended to include corrected QT
interval >450ms
22.Clinically relevant out-of-range values in ay haematology, urinalysis or clinical chemistry tests
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cellulose. Matching placebo capsules were also manufactured with
identical visual characteristics to ensure a blinded placebo-
controlled study. Capsules were packed in an opaque white, high
density polyethylene bottle with child-resistant closures that were
induction sealed. Participants were instructed to take, with food,
4 200mg capsules of AUT00063 once daily to achieve the 800mg
dose. At the end of the D1 visit, participants were given 27 days of
study medication (plus 4 extra capsules).
2.5. Outcomes
The primary endpoint was the difference between groups in themean change from D1 to D28 of tinnitus symptom severity, as
measured by the Tinnitus Functional Index (TFI) global score
(Meikle et al., 2012). To reduce risk of bias due to participants
inﬂating the self-reported severity of their tinnitus symptoms in
order to be enrolled onto a trial, the pre-intervention baseline (D1)
measure of the TFI was pre-determined after enrolment into the
trial. Exploratory analyses of the TFI investigated subscale scores
and binary outcomes according to whether individual treatments
were successful (change in TFI  13 points) or not (þ10 points).
TFI was selected because it assesses a range of tinnitus symptoms
experienced over the preceding week and had some prior clinical
evidence on which to estimate sample size to detect treatment-
related change (Fackrell et al., 2016; Meikle et al., 2012). Twenty-
Fig. 1. Schedule of the clinical research activities to be undertaken by each participant during the QUIET-1 trial, with details of the individual assessments conducted at each visit.
Superscript numbers denote the following: 1training baseline assessments may be carried out on the same day as screening; 2brief physical examination; 3pre-dose assessment;
4includes urine pregnancy test for women of child-bearing age; 5includes serum pregnancy test for women of child-bearing age; 6to be taken before last dose; 7at Nottingham site
only; 8up to 8 h post-dose assessment depending on participant's availability; 9distributed before discharge on Day 1; and 10optional assessment according to participant's
availability.
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cognitive interference, sleep disturbance, auditory difﬁculties, dif-
ﬁculties relaxing, quality of life, and emotional distress). Each item
is scored on an 11-point Likert scale, giving a global score from 0 to
100, and with higher scores indicating greater symptom severity.
For a UK clinical population of adults with tinnitus, the TFI has been
conﬁrmed to have high construct validity (correlation with the
Tinnitus Handicap Inventory, r¼ 0.80), high internal consistency
(a 0.95), and high test-retest reliability (intraclass correla-
tion¼ 0.87) (Fackrell et al., 2018).Tinnitus loudness was the secondary clinical efﬁcacy endpoint
(D1 to D28), measured by adjusting the level of a tone until its
loudness was “about the same loudness” as the participant's
tinnitus. Estimates of tinnitus loudness largely depend on the type
of measurement used and at the time of study design it was unclear
which available procedures had acceptable reliability and validity.
Choice of loudness-matching technique was informed by the pro-
cedure developed at the Oregon Tinnitus Clinic (Vernon andMeikle,
1981). The modiﬁed procedure required testing, in 2 dB-steps, only
at 1 kHz in the non-tinnitus ear (or ear where the tinnitus was least
Table 2
Recruiting NHS sites across England.
Site code Date opened to enrolment Patients assessed for eligibility at screening visit (n¼ 212) Randomised to AUT00063 (n¼ 44) Randomised to placebo (n¼ 47)
03 10/10/2014 22 7 4
09 10/10/2014 12 5 1
08 17/10/2014 14 2 6
02 23/10/2014 32 7 7
04 27/10/2014 27 9 6
10 03/11/2014 13 3 3
06 06/11/2014 4 0 1
13 21/01/2015 9 0 4
12 11/02/2015 7 1 1
01 17/02/2015 28 4 3
17 23/04/2015 6 1 2
18 14/05/2015 14 3 3
14 22/06/2015 2 0 0
15 22/06/2015 10 1 3
19 28/07/2015 12 1 3
11 28/07/2015 0 0 0
05 25/08/2015 0 0 0
20 03/09/2015 0 0 0
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recruitment since 1 kHz is a frequency generally within the normal
hearing range and also well below the typical pitch match fre-
quency. To familiarise participants with the procedure enhancing
stability of the baseline measure, loudness matching was
completed during the training baseline visit. This datawas not used
in the analysis.
To promote data quality, a Study Procedures Manual for audi-
ology assessments was created and all relevant trial staff across the
sites were trained in study-speciﬁc procedures (TFI, loudness
matching, and estimating lifetime noise exposure) by a member of
the Nottingham team. Noise exposure was assessed using a struc-
tured interview that consider all activities across the lifespan that
the respondent had experienced as noisy (deﬁned based on sound
level estimated from vocal effort) (Lutman et al., 2008). A list of
Frequently Asked Questions encouraged consistency across the trial
sites by sharing responses to audiology-related queries, especially
on the noise exposure procedure. Pure Tone Average and TFI global
scores could differ across Screening and D1 visits due to test-retest
variability. Participants, who were eligible for inclusion at
Screening but not at D1, were recommended for randomisation, but
any uncertainties by the trial team or unexpectedly large differ-
ences were referred to the Sponsor.
The other secondary clinical efﬁcacy endpoints (D1 to D28)
concerned the safety and tolerability proﬁle of AUT00063. These
questions were assessed by medically qualiﬁed members of the
study team in terms of effects on vital signs (i.e. systolic blood
pressure, diastolic blood pressure, heart rate andtemperature),
physical examination (i.e. lymph nodes, gastrointestinal, cranial
nerves, peripheral nervous system, heart, chest, ears and general
appearance), and laboratory exams (i.e. serum biochemistry, serum
haematology, and urinalysis). Electrocardiogram (ECG) (including
corrected QT interval (QTc) which is an index of cardiac repolar-
isation) was collected at the screening visit and Day 42. Data on
Adverse Events (AEs) and Serious Adverse Events (SAEs) were also
captured throughout the trial. An AE was deﬁned as any unfav-
ourable and unintended sign, symptom or disease temporarily
associated with the intervention, whether or not it was considered
related to the medicinal product. It was rated as mild, moderate or
severe by the sitesite Investigators. An SAE was life-threatening or
resulted in death, resulting in hospitalisation or prolongation of
existing hospitalisation, resulted in persistent or signiﬁcant
disability or incapacity, was a congenital anomaly or birth defect or
was otherwise considered medically important. Treatment-emergent AEs were those that started or increased in severity on
or after the ﬁrst dose of study medication.
Exploratory outcomes were the blood plasma concentration of
AUT00063 as a marker for drug exposure, overall patient-reported
experience of treatment-related change and neural activity. Blood
plasma concentration of AUT00063 was measured in ng/ml at a
pre-dose time point on D28. Samples were stored and dispatched to
a commercial company (Aptuit) for analysis. On D28, participants
were also asked to reﬂect on whether they had experienced any
treatment-related change using the Clinical Global Impression
(Improvement) scale. This is a single 7-point Likert scale with cat-
egories from ‘much worse’ to ‘much better’, with ‘no change’ at the
mid-point. Finally, neural activity was assessed by pre- and post-
dosing by pharmacoEEG and Auditory Brainstem Response
recording. Only seven participants completed the electrophysiology
assessments at one recruiting site, and so the data are inconclusive
(not reported).
2.6. Sample size
The analysis of the primary outcome was planned for an
ANCOVA of the global TFI change from D1 to D28, controlling for
randomisation strata and baseline covariates to estimate the mean
difference between the AUT00063 and placebo groups. Sample size
estimation was based on unpublished data from a large UK sample
of people with tinnitus (n¼ 285 enrolled from the general popu-
lation into a trial, ClinicalTrials.gov Identiﬁer: NCT01541969 and
n¼ 151 recruited via audiology clinics). The mean global TFI score
for this group was 44.9 points (SD 21.2). The minimum clinically
important beneﬁt was taken to correspond to a reduction in the
group mean TFI of 13 points (Meikle et al., 2012).
Based on a two-group t-test, a sample size calculation deter-
mined that 57 participants would be required per treatment arm to
detect a statistically signiﬁcant difference between AUT00063 and
placebo groups (nQuery Advisor 5.0, Statistical Solutions Ltd). This
calculation was based on the above information as well as a 1:1
treatment allocation and a two-sided hypothesis with 90% power at
an alpha level of 0.05. Accounting for a planned interim futility
analysis (see section 2.7) indicated that 59 participants per arm
were required. The permitted sample size was increased to 76 per
group (152 in total) in order to mitigate a number of operational
risks. These were that: i) the study sample may not adequately
match the reference population in terms of the assumed distribu-
tion of TFI scores and heterogeneity in other relevant
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and iii) any subsequent upward adjustment of the sample size
(potentially arising from recommendations of the planned interim
analysis) would have severe project management implications.
2.7. Interim analysis and stopping rules
One interim analysis of the primary endpoint and safety data
was planned for when approximately 50% of the participants had
completed D28. Statistical signiﬁcance and futility boundaries were
estimated for the interim and ﬁnal analysis based on 50,000 sim-
ulations from the PASS® software (NCSS, Kaysville, Utah) by simu-
lating a group sequential test for two means assuming normality
testing. At the interim analysis, the two-sided signiﬁcance bound-
ary for clinical efﬁcacy was 0.00312 and for futility of detecting
mAUT00063> mplacebo, the one-sided O'Brien-Fleming boundary was
0.39,141. Hence, at the ﬁnal analysis, the two-sided signiﬁcance
boundary for clinical efﬁcacy would be 0.04761. The Independent
Data Monitoring Committee (IDMC) was advised to consider
making recommendations for early termination only where there
was a clear demonstration of futility.
2.8. Randomisation and blinding
Participants were randomised using a computer-generated
allocation sequence that was managed within a telephone-based
central randomisation service (http://www.sharpservices.com/).
Participants were randomly assigned to either AUT00063 or pla-
cebo groups with a 1:1 allocation. Minimisation techniques were
used to balance allocation to the two arms according to four
stratiﬁcation variables assessed at the screening visit: (i) age (<65
years, 65 years), (ii) gender (male, female), (iii) average hearing
loss (mild¼40 dB and moderate¼41 dB), and (iv) tinnitus
symptom severity as measured by the global TFI (slight-moder-
ate¼ 24e35.4, and moderate-severe¼ 35.5e68). For the mini-
misation procedure only, average hearing loss was deﬁned by the
Pure Tone Average of air-conduction thresholds at six frequencies
(0.5,1, 2, 4, 6 and 8 kHz), averaged across the two ears. This measure
captured threshold sensitivity at both low and high frequencies
considered relevant to the underlying pathophysiology targeted by
AUT00063.
The Sponsor, the Contract Research Organisation responsible for
monitoring the study, pharmaceutical services staff and local study
site personnel were all blinded to treatment allocation, with audit
trails to conﬁrm no unblinding of participants. Thus, randomisation
was conducted without any inﬂuence of the Sponsor or local study
site personnel. According to the Clinical Trial Protocol, several in-
dividuals were unblinded: i) the clinical project controller for the
telephone-based central randomisation service, ii) two Contract
Research Organisation statisticians working on processing and
analysing the primary outcome, safety and harms data for the
planned interim analysis presented to the IDMC, and iii) two Con-
tract Research Organisation biostatisticians who prepared all the
Tables and Listings after termination of the trial and database lock.
To safeguard the integrity of the trial, the statistical teamteam
preparing thethe interim analysis were independent from the Data
Management team.
2.9. Data monitoring and ﬁdelity of the trial procedures
The majority of the participant data was entered into an elec-
tronic Case Report Form (eCRF) database maintained by a Contract
Research Organisation. ECG tracings and reports were separately
managed through a clinical study portal and database sub-
contracted to ERT (www.ert.com/), while EEG recordings for theNottingham site were managed by Biotrial (www.biotrial.com/).
ERT and Biotrial are specialists in conducting clinical trials to reg-
ulatory standards. Data monitors in the Contract Research Organi-
sation, ERT and Biotrial data management teams remotely
monitored data and sent regular queries to local trial sites when
data entry discrepancies were suspected. Site monitoring visits
were also performed generally every three weeks or according to
recruitment rate against a Monitoring Plan by Clinical Research
Associates acting on behalf of the Contract Research Organisation.
The purpose of these visits was to verify site data by cross-checking
all source data against the eCRF. The Principal Investigator at each
site reviewed and approved every page of the eCRF.
There was continual oversight of participant safety and of the
safety data. A medical monitor reviewed all laboratory test results
and safety data bi-weekly, sending data queries to local trial sites. In
addition, the medical monitor addressed queries about eligibility
and dealing with adverse events and adverse reactions. The
Sponsor‘s Chief Medical Ofﬁcer was in monthly contact to ensure
any potential safety data trends were identiﬁed and that all adverse
events were rigorously checked. An annual safety assessment and
six-monthly line listing was sent to all local recruiting sites after
submission to the relevant regulatory bodies (MHRA, NRES). The
integrity of the blood samples was monitored by recording detail-
ing dosage levels and timings, storage temperature, and details of
the transit of the samples from each trial site to BIOLIM, the sub-
contracted company conducting the analysis (http://www.biolim.
pl). Aptuit (a pharmaceutical services company, www.aptuit.com)
cross-referenced these data against the telephone-based central
randomisation service data.
A full audit to verify the compliance of the Trial Master File was
conducted after the planned interim analysis and decision to
terminate the study early by the Contract Research Organisation.
This process was assessed by the Sponsor.
2.10. Statistical methods
Safety and tolerability of AUT00063 were investigated using the
‘Safety Analysis Set’ which included all enrolled participants who
had received at least one dose of study medication.
Clinical efﬁcacy analysis using analysis of covariance (ANCOVA)
was planned for a ‘Per Protocol Set’ which should include those
participants meeting all inclusion criteria, completing at least one
post-baseline measurement for the primary efﬁcacy variable, and
with no major protocol violations. Because the trial was terminated
early and there was no Blinded Data Review Meeting, we were
unable to conduct a ‘Per Protocol’ analysis as intended. Instead, the
primary efﬁcacy analysis was conducted using the ‘Full Analysis Set’
which included those participants who received at least one dose of
study medication, and completed at least one post-baseline mea-
surement for the primary efﬁcacy variable. All analyses were con-
ducted by a trial statistician who was blinded to the group
allocation and followed the pre-deﬁned Statistical Analysis Plan.
Details of the characteristics of the Full Analysis Set, as assessed at
the screening visit, are given in Table 3. Missing data were not
imputed and so complete case analyses are reported. Notably, eight
participants had missing noise exposure estimates (the covariate of
interest) and so a total of 68 datasets were available for this anal-
ysis. ANCOVA ﬁndings were also conﬁrmed for a ‘Completers
Population’ which was deﬁned as the subset of those participants
who completed the full 28 days of study treatment (n¼ 63).
The planned ANCOVA accounted for the four minimisation
variables (i.e. age, gender, hearing status and tinnitus symptom
severity) to allow systematic and random variability to be sepa-
rately estimated (Taves, 1974). To improve the precision of the es-
timate of clinical efﬁcacy of the drug treatment, analysis also
Table 3
Demographics and characteristics of the Full Analysis Set assessed at the screening visit. A noise exposure estimate of 1.0 denotes an equivalent lifetime exposure to occu-
pational, recreational and ﬁrearm noise (8 h per day, 5 days per week, 48 weeks per year over a 50-year working lifetime) corresponding to 81e90 dB (A). For more details of
the calculation and interpretation of lifetime noise exposure, see Lutman et al. (2008).
AUT00063 (n¼ 36) Placebo (n¼ 40)
n Mean (SD) n Mean (SD)
Age (years) 36 52.78 (11.27) 40 55.23 (10.56)
Gender 36 9 female; 27 male 40 8 female; 32 male
Height (cm) 36 176.17 (7.45) 40 174.83 (9.34)
Weight (kg) 36 86.58 (20.37) 40 85.03 (18.31)
Body Mass Index (kg/m2) 36 27.72 (5.68) 40 27.88 (5.87)
Hearing loss (deﬁned by the pure tone average 0.5e4 kHz across both ears, dB HL) 36 19.74 (11.64) 40 21.28 (11.42)
Noise exposure estimate (0e4) 35 1.0 (0.92) 33 0.9 (0.91)
Duration of noticeable tinnitus symptoms (years) 36 1.0 (0.37) 40 1.1 (0.32)
Tinnitus Functional Index (0e100) 36 42.01 (12.45) 40 45.44 (11.86)
Depressive subscale of Hospital Anxiety and Depression Scale (0e21) 36 3.36 (2.59) 40 2.88 (2.42)
Anxiety subscale of Hospital Anxiety and Depression Scale (0e21) 36 4.97 (3.27) 40 4.40 (2.59)
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to inﬂuence the primary outcome; the baseline (D1) TFI global
score, duration of noticeable tinnitus symptoms, and noise expo-
sure estimate. These covariates were chosen based on informed
expert opinion of the study team and the Scientiﬁc Advisory Board.
Noise exposure was an indicator for the degree of noise-related
cochlear damage, which relates to the underlying pathophysi-
ology targeted by AUT00063.
3. Results
The number of randomised participants was not sufﬁcient to
achieve the statistical power determined by the sample size
calculation. This was a consequence of the premature termination
of the study resulting from futility in the planned unblinded
interim analysis. The interim analysis was conducted by the IDMC,
who reviewed unblinded safety and primary efﬁcacy outcome (TFI)
data from 58 participants. The recommendationwas to discontinue
the QUIET-1 trial based on efﬁcacy data, as the p-value of the pri-
mary analysis had exceeded the futility boundary stated in the
IDMC charter. No safety issues were identiﬁed. On the basis of this
recommendation and following an internal review of the data by
the Sponsor, the Sponsor decided to terminate enrolment into the
QUIET-1 trial early; 91 participants had been enrolled.
3.1. Participant ﬂow
In total, 212 participants were consented across the 15 of the
centres opened for recruitment. Two additional participants were
assessed for eligibility, but without written informed consent, and
so their data was not included. These two participants also failed to
meet the inclusion criteria at the eligibility assessment. In total
therefore, 123 participants were excluded at the eligibility assess-
ment (visit 1). Fig. 2 provides primary reasons for exclusion. Where
several reasons were given for an individual, the major reason was
recorded as the ﬁrst one given in the sequential order of the study
protocol (seven inclusion and 22 exclusion criteria). “Other rea-
sons” included two participants who were referred to their General
Practitioner for further assessment before being eligible for
rescreening, three participants who needed rescreening, and one
who was unwilling to comply with the Clinical Trial Protocol
regarding alcohol intake.
Of the 91 participants randomised, all received at least one dose
of study medication and so these comprised the Safety Analysis Set.
Fifteen participants did not complete the study to D28 and so the
Full Analysis Set comprised 76 participants. Of these, ﬁve
(AUT00063¼ 4; Placebo¼ 1) interrupted their treatment scheduleand did not complete the full 28-day prescription. These were
excluded from the Completers Population.
3.2. Characteristics of the Full Analysis Set (n¼ 76)
Overall, the mean (median) age was 54.07 (55) years and ranged
from 27 to 76. There was a substantial preponderance of men:
n¼ 61 (80.3%) versus n¼ 15 (19.7%) women. The majority of par-
ticipants (n¼ 65, 85.5%) were aged less than 65 years. All partici-
pants were of Caucasian ethnic origin, with the exception of a single
Asian male allocated to the placebo group. There were no notable
differences between the treatment groups for these baseline de-
mographic variables or for height, weight and Body Mass Index.
Data for the key demographic and clinical characteristics of the 76
participants in the Full Analysis Set are reported in Table 3. Eight
participants did not have noise exposure estimates. Three of these
reported having experienced an explosion and so exposure could
not be estimated reliably, following Lutman et al. (2008). The
remaining ﬁve had missing data (see section 3.4 for more details).
The characteristics of the Safety Analysis Set (n¼ 91) were
comparable to the Full Analysis Set. Mean (median) age was 54.16
(55) years, with 85.7% aged less than 65 years. Again, there were
almost four times more men (n¼ 71, 78.0%) than women (n¼ 20,
22.0%). Baseline tinnitus symptom severity was 42.3 (12.5) in
AUT00063 and 46.6 (11.6) in placebo.
3.3. Fidelity of implementing the intervention
Two deviations were noted by the Sponsor during the conduct
of the study.
Initially the Clinical Trial Protocol allowed for D28 (endpoint)
visit to be conducted on Days 26, 27 or 28, while the amendment in
version 1.5 dated 02 July 2015 extended this to allow an endpoint
visit on Day 29. At several sites, when the endpoint visit was on Day
29, some participants took the four extra capsules which consti-
tuted a 29th day of dosing. This was not deemed critical to the
scientiﬁc interpretation of clinical efﬁcacy or to participant safety;
participants were included in the Completers Population analysis.
The second deviation pertained to those ﬁve participants who
interrupted their treatment schedule and did not complete the full
28-day prescription. To verify that this did not bias the main study
ﬁnding, these were excluded from an analysis of the Completers
Population.
3.4. Fidelity of the research assessments
A full ‘Per Protocol’ evaluation was not conducted, but three
Fig. 2. Flow of participants in the QUIET-1 clinical trial. The study was terminated by the Sponsor after the interim analysis for futility which accounts for some of the participants
who did not complete all scheduled visits Two participants were randomised but subsequently withdrawn at Sponsor request for administrative reasons.
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during the conduct of the study. None of thesewere deemed critical
to the scientiﬁc interpretation of clinical efﬁcacy or to participant
safety. First, according to the Clinical Trial Protocol the audiological
assessment at the screening visit requiredcalculating a four-
frequency pure tone average for determining eligibility (see
Table 1 Inclusion criterion 4a), and a six-frequency pure tone
average for determining stratiﬁcation using the telephone-based
central randomisation service (see section 2.8). Sometimes this
information from the D1 visit was used instead. Similarly, the TFI
global score at D1 was sometimes used for stratiﬁcation. Descrip-
tive data for the baseline D1 visit were carefully investigated to
examine how well balanced was the hearing loss and tinnitus
symptom severity across the two groups. Moreover, a post-hocanalysis conﬁrmed that these deviations did not impact on partic-
ipant eligibility (not reported). Second, one participant allocated to
AUT00063 had depression and anxiety scores outside the eligible
range (scores 11 and 15, respectively), while one participant allo-
cated to placebo should have been excluded for high anxiety
(score¼ 11). Both contributed to the Completers Population. Third,
for the noise exposure estimate, data for ﬁve participants were
coded as N/A in the electronic case report form (one on AUT00063
and four on placebo). For these participants, it was unclear whether
noise exposure did not reach eligibility for recording (i.e.
80 dB(A)), or whether the structured interview was not
completed, and so the noise exposure estimate was counted as a
missing data entry (and data were excluded from the ANCOVAs for
the Full Analysis Set and the Completers Population).
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Treatment-related change in the global TFI score showed no
statistically signiﬁcant difference between AUT00063 800mg
once-daily and placebo groups in the Full Analysis Set (Table 4). The
adjusted mean difference in TFI was 1.56, p¼ 0.678 and the 95%
conﬁdence interval around the mean difference was 5.90 to 9.01.
The ANCOVA for the Completers Population (n¼ 71) gave an almost
identical null result (Table 4).
Therewas no effect of AUT00063 on the tinnitus loudnessmatch
in the Full Analysis Set. The adjusted mean loudness match differ-
ence between AUT00063 and placebo groups was 1.22 dB SL,
p¼ 0.530 and the 95% conﬁdence interval around this mean dif-
ference was 5.10 to 2.65. Worthy of note, tinnitus symptoms
measured by TFI and loudness matching did not change over the
four weeks of treatment for either treatment group (see Table 5).
This lack of a ‘placebo’ effect is considered in the Discussion.
3.6. Adverse events (AEs)
Safety and tolerability data from the Safety Analysis Set indi-
cated that AUT00063 at 800mg once-daily for 28 days was
acceptable. Overall there were 177 recorded treatment-emergent
AEs (AUT00063¼115; placebo¼ 62), reported across 32 of the 44
participants receiving AUT00063 and 23 of the 47 participants
receiving placebo (Table 6). The majority of AEs were of mild
severity (mild¼ 125; moderate¼ 29; severe¼ 21; uncoded¼ 2)
and symptoms recovered or resolved without any need to change
the dose. Headaches and dizziness are thought to be related to
treatmentwith AUT00063 and are an expected side effect when not
overly severe. Headaches were reported in similar numbers across
the AUT00063 and placebo. Treatment with AUT00063 was asso-
ciated with dizziness in seven participants receiving AUT00063
(15.9%), none on placebo. Incidence of gastrointestinal disorders
and of infections was higher in participants treated with AUT00063
than in those treated with placebo. Gastrointestinal disorders were
reported by 10 participants (22.7%) on AUT00063 and ﬁve (10.6%)
on placebo, while infections were reported by nine participants
(20.5%) on AUT00063 and two (4.3%) on placebo. Due to the nature
and variety of the gastrointestinal disorders and infections, it is not
thought that these treatment-emergent AEs were attributable to
treatment with AUT00063.
The reporting frequency of SAEs was similar between AUT00063
and placebo, with one SAE being reported by one participant in
each treatment group: placebo (2.1%, pyrexia of unknown origin,
related); AUT00063 (2.3%, anxiety, not related). There were no
deaths or other signiﬁcant AEs reported during the study. The
overall safety-related withdrawal rate was approximately 4%, and
was similar between active and placebo groups. Analysis of vital
signs, ECG and laboratory parameters did not reveal any clinically
signiﬁcant pattern in participants treated with AUT00063. For
example, no abnormal heart rate was recorded on physical exam-
ination and changes in heart rate from screening were negligible atTable 4
Analyses examining the overall effect of AUT00063 compared to placebo (D2
adjusted mean difference indicates a smaller decrease in tinnitus symptom
negative mean difference.
Comparison A
Es
Full Analysis Set
AUT00063 versus placebo, TFI global score 1.
AUT00063 versus placebo, tinnitus loudness 
Completers Population
AUT00063 versus placebo, TFI global score 1.D1 and D28, in AUT00063 and placebo groups.
3.7. Planned exploratory outcomes
Findings from the exploratory analyses were as follows:
i) Pharmacokinetic analysis of the plasma concentration of
AUT00063 for the Safety Analysis Set assessed at D28 (n¼ 38)
revealed good exposure levels following treatment with
AUT00063, with mean (median) plasma levels of AUT00063
of 4818.82 (4704.50) ng/ml; range 119.90e8011.30.
ii) For the eight TFI subscale scores, descriptive data for the Full
Analysis Set are summarised in Table 7. Small reductions in
scores were observed across most subscales from dosing day
(D1) to D28, but for both treatment groups. Large standard
deviations limit interpretation (c.f. Fackrell et al., 2016, 2018).
iii) The Full Analysis Set was subjected to exploratory analyses of
success rate using two logistic regressions with the following
predictors: treatment (AUT00063 vs placebo), gender (fe-
male vs male), age (years), tinnitus duration (years), func-
tional impact of tinnitus (global TFI score), and degree of
sensorineural hearing loss (pure tone average dB HL). Results
are reported in Table 8. The ﬁrst explored whether one might
predict the binary outcome ‘improver’ from ‘non-improver’.
Five of the 36 participants in the AUT00063 group (13.9%)
and eight of the participants in the placebo group (20.0%)
suggested an ‘improvement’ deﬁned by an individual
treatment-related change in TFI13 points. Remaining
participants were classed as ‘non-improvers’. Only tinnitus
symptom severity was a predictor of improvement
(p¼ 0.0268).
It was possible that there was a small subgroup of people with
subjective tinnitus who didworse on AUT00063. Three participants
(3/76¼ 3.9%) treated with AUT00063 rated their tinnitus as “much
worse” using a measure of the Clinical Global Impression
(Improvement) scale at D28, compared to no participants on pla-
cebo. These participants also had a corresponding TFI change of >10
points (i.e.10.8,11.2, and 22 points respectively). The second logistic
regression therefore explored whether one might predict the bi-
nary outcome ‘worsener’ from ‘non-worsener’ (Table 8). Eight of
the 36 participants in the AUT00063 group (22.2%) and ﬁve of the
participants in the placebo group (12.5%) suggested a ‘worsening’
deﬁned by an individual treatment-related change in global TFI
score (þ10 points). Remaining participants were classed as ‘non-
worseners’. Results showed no statistically signiﬁcant effect, indi-
cating an absence of any speciﬁc predictive characteristics for
treatment-related change.
The Clinical Global Impression (Improvement) scale ratings
were interrogated more broadly across the Full Analysis Set. A total
of eight participants (8/76¼10.5%) rated their tinnitus as ‘slightly
improved’; one participant (1/36¼ 2.8%) in the AUT00063 group
and seven (7/40¼17.5%) in the placebo group. All other ratings8-D1) for the Full Analysis Set and the Completers Population. A positive
severity in the AUT00063 group compared to placebo. Vice-versa for a
djusted mean difference
timate (95% CI) P-value (two-sided)
56 (5.90 to 9.01) 0.678
1.223 (5.10 to 2.65) 0.530
92 (5.53 to 9.36) 0.608
Table 5
Analyses examining the change from dosing day (D1) to study end point (D28) on the primary and secondary efﬁcacy endpoints for the Full Analysis Set. CI ¼ Conﬁdence
Interval. ND ¼ Not Done. A negative mean difference indicates a decrease in tinnitus symptom severity.
Comparison D1 mean (SD) D28 mean (SD) n Adjusted mean D28 mean (SD)
Estimate (95% CI) P-value (two-sided)
Full Analysis Set
AUT00063, TFI global score 41.82 (14.03) 40.25 (17.02) 36 2.80 (10.84 to 5.24) 0.489 40.63 (19.69)
Placebo, TFI global score 45.66 (14.10) 39.87 (17.39) 40 4.35 (12.67 to 3.96) 0.299 40.04 (18.19)
AUT00063, tinnitus loudness (dB SL) 17.37 (9.83) 15.40 (10.43) 34 1.51 (3.10 to 6.13) 0.514 ND
Placebo, tinnitus loudness (dB SL) 16.03 (10.50) 16.18 (9.63) 39 2.74 (2.40 to 7.87) 0.290 ND
Completers Population
AUT00063, TFI global score 42.66 (14.330) 42.82 (15.279) 32 0.09 (8.10 to 7.91) 0.981 43.35 (18.112)
Placebo, TFI global score 45.22 (13.999) 38.89 (16.468) 39 2.01 (10.98 to 6.96) 0.655 39.52 (18.147)
Table 6
Summary of treatment emergent AEs that occurred in5% of the Safety Population. AEs are coded using the Coding DictionaryMedDRAVersion 17.0 (or higher). Counting is on
a per-participant basis. If a participant reported the same event repeatedly then the event was counted only once.
System Organ Class
Preferred Term
AUT00063 (N¼ 44) n (%) Placebo (N¼ 47) n (%) Overall (N¼ 91) n (%)
Number of participants with at least one treatment emergent AE 32 (72.7) 23 (48.9) 55 (60.4)
Nervous System Disorders 20 (45.5) 10 (21.3) 30 (33.0)
Headache 13 (29.5) 9 (19.1) 22 (24.2)
Dizziness 7 (15.9) none reported 7 (7.7)
Gastrointestinal Disorders 10 (22.7) 5 (10.6) 15 (16.5)
Nausea 4 (9.1) 1 (2.1) 5 (5.5)
Infections and Infestations 9 (20.5) 2 (4.3) 11 (12.1)
Nasopharyngitis 4 (9.1) none reported 4 (4.4)
Ear and Labyrinth Disorders 5 (11.4) 4 (8.5) 9 (9.9)
Ear Pain 3 (6.8) 1 (2.1) 4 (4.4)
Respiratory, Thoracic And Mediastinal Disorders 7 (15.9) 1 (2.1) 8 (8.8)
Oropharyngeal Pain 3 (6.8) 1 (2.1) 4 (4.4)
Table 7
Summary of the changes from dosing day (D1) to study end point (D28) on the TFI subscale scores for the Full Analysis Set. SD¼ standard deviation. A negative mean difference
indicates a decrease in symptom severity.
TFI subscale n AUT00063, mean (SD) n Placebo, mean (SD)
Intrusiveness 35 2.33 (17.238) 40 3.58 (13.989)
Sense of control 36 2.69 (22.191) 40 9.43 (23.693)
Cognitive interference 36 2.36 (17.313) 40 8.70 (17.611)
Sleep disturbance 36 4.99 (22.073) 40 3.50 (13.495)
Auditory difﬁculties attributed to tinnitus 36 2.00 (20.656) 40 3.20 (15.914)
Relaxation 36 3.51 (23.977) 40 8.75 (20.233)
Tinnitus-speciﬁc ‘quality of life’ 36 1.66 (14.983) 40 3.83 (16.384)
Emotional distress 36 2.83 (21.194) 40 5.75 (16.282)
Table 8
Summary of the logistic regression analyses for the Full Analysis Set to predict improvers/non-improvers and worseners/nonworseners. * denotes signif-
icance at p < 0.05.
Odds ratio
Predictor variable Estimate (95% CI) P-value
Improvers vs non-improvers
Treatment (AUT00063 vs Placebo) 0.586 (0.151e2.277) 0.1007
Gender (female vs male) 1.092 (0.223e5.341) 0.9132
Age (years) 1.069 (0.987e1.158) 0.1007
Tinnitus duration (years) 0.214 (0.028e1.647) 0.1386
Functional impact of tinnitus (global TFI score at D1) 1.068 (1.008e1.132) 0.0268*
Degree of sensorineural hearing loss (pure tone average dB HL) 0.992 (0.928e1.061) 0.8252
Worseners vs non-worseners
Treatment (AUT00063 vs Placebo) 2.078 (0.589e7.330) 0.2555
Gender (female vs male) 1.207 (0.280e5.215) 0.8007
Age (years) 1.007 (0.941e1.078) 0.8348
Tinnitus duration (years) 1.607 (0.255e10.118) 0.6132
Functional impact of tinnitus (global TFI score at D1) 1.018 (0.966e1.072) 0.5011
Degree of sensorineural hearing loss (pure tone average dB HL) 0.968 (0.903e1.037) 0.3524
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with the null ﬁndings on the planned statistical analyses.
4. Discussion
4.1. Main observations
QUIET-1 was a carefully designed multi-centre phase IIa clinical
trial that followed a pre-speciﬁed Clinical Trial Protocol and Sta-
tistical Analysis Plan, and was statistically powered to detect a
difference between experimental and placebo groups. The ﬁndings
produced a clear outcome. While the pharmacokinetic analysis
conﬁrmed systemic exposure to AUT00063 within the predicted
therapeutic range, AUT00063 was not effective in alleviating the
symptoms of subjective tinnitus at this dose level. The trial was
stopped early for futility, a decision which was based on both
ethical and resource perspectives. The results indicated that the
daily dose of 800mg capsules of AUT00063 taken for 28 days was
safe and well tolerated, with themost common expected side effect
(dizziness) being mild in nature, with these symptoms resolving
without the need to stop or change dosing. We acknowledge that a
28-day study in 91 participants is not sufﬁcient to exclude long-
term safety concerns or rare adverse reactions.
4.2. Reﬂections on bridging the gap between animal and human
research
First, systemic drug exposures to AUT00063 achieved in subjects
in the QUIET-1 trial were comparable to those achieved in rodent
models. Speciﬁcally, the plasma levels of AUT00063 in QUIET-1
participants were similar to those achieved in rodents following a
30mg/kg i.p. dose which was effective at reducing spontaneous
neuronal ﬁring in noise-exposed hamsters (Glait et al., 2018). These
data support the conclusion that appropriate drug concentrations
were likely to have been achieved in the central nervous system.
However, whether or not these concentrations were sufﬁcient to
achieve the required engagement with the biological target could
not be ascertained from the current data. A potential biomarker for
target engagement (pharmacoEEG) was included in the trial pro-
tocol, but these measures were only achieved for seven partici-
pants, and thus were not informative.
Several important aspects of preclinical data did not translate
well from animal to human. Using the available preclinical data
from rodent models, the prediction about the human therapeutic
beneﬁts of AUT00063 for tinnitus had been inferred from data
gathered on a surrogate neurobiological marker (i.e. reduction in
spontaneous hyperactivity in the brainstem and midbrain)
(Anderson et al., 2018; Glait et al., 2018). It was always realised that
this prediction had a number of important caveats, since the exact
neural substrate of subjective tinnitus is unknown. One caveat
concerns the principle that spontaneous hyperactivity plays a
determining role in tinnitus. Other neural mechanisms are likely to
be implicated. For example, Roberts et al. (2010) concluded that
neural synchrony in spontaneous ﬁring may be the more promi-
nent neural correlate of tinnitus because it is more likely to impact
postsynaptic targets and recruit cortical and downstream neurons
into a tinnitus percept. Changes in spontaneous neural synchrony
also precede hyperactivity in an acute preparation of noise-induced
tinnitus, following more closely the perceptual experience of
tinnitus (Eggermont, 2013). In 2013, Eggermont reviewed a series of
animal studies that had collected data using electrophysiological
recordings and behavioural tests in the same animals (Eggermont,
2013). Findings indicated a discrepancy between putative cortical
electrophysiological correlates of tinnitus and presumed behav-
ioural ones, leading Eggermont to conclude that cortical measuresof spontaneous hyperactivity and neural synchrony seem to be
correlates of hearing damage through noise exposure, rather than
of tinnitus per se. While most of the discrepancies would disappear
if neural activity in subcortical structures were taken to be themain
determinant of performance on behavioural tests, but then this
would call into question the role of cortical processing in the
perception of tinnitus. The search for neural signature of tinnitus
requires animal models that show reliable and robust behavioural
evidence of subjective tinnitus, under conditions similar to those
that cause the condition in humans. The lack of a standard behav-
ioural model is yet another challenge to be solved in order to make
substantive advances in drug development for tinnitus. In the
meantime, more direct measures of auditory subcortical activity in
people with tinnitus could allow better translation of rodent study
results in humans (Glait et al., 2018), but again these techniques too
are not without challenge (c.f. Pierzycki et al., 2016). A ﬁnal caveat
concerns the equivalence of single (acute) and repeated (chronic)
dosing. As Glait et al. (2018) point out; the rodent model used an
acute dosing of AUT00063, whereas the QUIET-1 trial design used a
chronic dosing in humans. The persistence of the neurobiological
effects of AUT00063 is not known since that experimental work has
not yet been done. These uncertainties suggest that the conﬁdence
in the predictive validity of certain animal models of noise-induced
hearing loss and tinnitus were perhaps somewhat optimistic.
We conclude that, despite a compelling body of in vitro and
in vivo rodent data from models of noise-induced hearing loss and
tinnitus supporting the neurobiological modulatory effects of
AUT00063 on central auditory pathologies, the drug did not in-
ﬂuence the subjective patient experience of tinnitus. The ﬁndings
from QUIET-1 underlie the general scientiﬁc challenge and com-
mercial risk in transitioning from preclinical drug development in
the animal model to clinical application in patients. Such challenge
and risk are certainly not restricted to hearing-related conditions
and arewidely acknowledged across any biological complex system
(e.g. Demetrius, 2005; Shanks et al., 2009).
4.3. Learnings about the design of phase IIa pharmaceutical trials in
tinnitus
When the QUIET-1 trial was designed there had been few
tinnitus trials with novel drugs on which to select an appropriate
study population, optimal outcome measures and sample size that
would assure an informative outcome from the trial and meet
regulatory standards. Several general literature reviews on tinnitus
trial design (e.g. Tyler et al., 2007; Landgrebe et al., 2012), and some
recent examples of phase II trials (e.g. Suckfüll et al., 2011) were
available, but therewas little consensus regarding optimal design. A
review of the strategies for recruiting participants into hearing-
related clinical trials have been published elsewhere (Sanchez
et al., 2018), and so here we reﬂect on the speciﬁc eligibility
criteria and the choice of outcome measures in the QUIET-1 trial.
The QUIET-1 trial was the ﬁrst study to evaluate AUT00063 in a
population of patients with tinnitus, and as such, was intended to
search for evidence of efﬁcacy. In the phase IIa stage of the drug
development pipeline, trials are designed to establish an answer to
the question about whether the preclinical theory can be translated
into human patients, and so they investigate whether the drug has
any potential therapeutic beneﬁt in a relatively homogeneous
population that might be most sensitive to the drug's mechanism of
action. A phase IIa study design is not intended to generate ﬁndings
that could be generalised to a broader tinnitus population. If the
drug fails in this stage, then it is very unlikely to succeed when the
variability of the patient group is broadened at the phase III stage. In
light of the context of its phase of development, the QUIET-1 trial
had more restrictive eligibility criteria than the usual clinical
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degree of tinnitus symptom severity, and degree of sensorineural
hearing loss in order to promote greater homogeneity. These were
all considered important baseline characteristics which could in-
ﬂuence sensitivity to drug treatment. These criteria were set to
balance the different needs of the trial against feasibility of assess-
ment and likelihood of recruiting the target number of patients.
The duration of tinnitus symptoms required for inclusion in the
QUIET-1 study was set to >6 months and <18 months. Although
somewhat arbitrary, these durations were chosen to exclude par-
ticipants with relatively acute tinnitus that might spontaneously
remit, and those with a long-standing tinnitus that may involve
different mechanisms to those responsible for the generation of
tinnitus and may be more resistant to change (Landgrebe et al.,
2012).
Regulatory approval for a new drug requires evidence that it
provides an important clinical beneﬁt. And so although AUT00063
targeted the central component of tinnitus associated with the
perception of tinnitus, the trial examined its indirect effects on
reactions to tinnitus as the primary outcomemeasure. The Tinnitus
Functional Index (Meikle et al., 2012) was chosen based on reports
of its sensitivity to treatment-related change and validity with
respect to other diagnostic measures of tinnitus (this is discussed
further below). Participants in the QUIET-1 trial were included with
a global TFI score 24 and 68. This range of scores was chosen to
reﬂect those who might be most likely to respond to treatment
based on raw data collected from 151 patients recruited from Na-
tional Health Service audiology clinics into a non-randomised
observational study (Fackrell et al., 2018) and 285 members of
the general public participating in a randomised controlled trial of a
novel tinnitus device (ClinicalTrials.gov Identiﬁer: NCT01541969)
(see Supplementary Material for the descriptive statistics used to
deﬁne the cut-offs). The assumption was that participants with
scores up to 24 would have little room to show improvement,
whereas those with TFI scores of 68 and above might require
additional clinical intervention that could interfere with the trial.
These choices seem reasonable given our later work showing that
global TFI scores up to 28 denote a small perceived problem, while
scores of 66 or more denote a very big problem in the same UK
population (Fackrell et al., 2018).
Finally, the inclusion criteria for hearing thresholds were set to
ensure the practicality of patient participation in the trial. An
important secondary efﬁcacy endpoint for the study was Tinnitus
Loudness Matching which required the participant to listen to
sounds and match their loudness to their subjective tinnitus
percept. Consequently, thresholds (see Table 1) were selected to
exclude participants with moderate to severe hearing loss, which
might interfere with their ability to participate in the trial.
Selecting outcomes which are relevant, appropriate and of
importance to patients in real-world clinical settings is a critical
design component. Indeed, it has been claimed that relatively few
trials make a meaningful contribution to patient care, often as a
result of the way that the trial outcomes are chosen, collected and
reported (Heneghan et al., 2017). For trials evaluating novel drug
products, the outcome must also satisfy the standards required by
the regulatory authorities. In current tinnitus practice, this means
choosing an outcome which demonstrates an improvement in
everyday functioning or quality of life and one that demonstrates a
reduction in the tinnitus percept.
With regards to everyday functioning or quality of life, a review
in 2010 (Kamalski et al., 2010) highlighted limitations in the evi-
dence to support the suitability of four of the most common multi-
item questionnaires in measuring changes in everyday tinnitus
symptom severity (Tinnitus Handicap Inventory, Tinnitus Handicap
Questionnaire, Tinnitus Reaction Questionnaire and TinnitusQuestionnaire). Prior to the QUIET-1 trial, the TFI had been devel-
oped as a new scale to be responsive to treatment related change
(Meikle et al., 2012). We therefore used the best available evidence
for what constitutes a clinically meaningful change in tinnitus
symptom severity and for the mean and standard deviation of
scores in a UK sample to select the TFI as the primary endpoint and
to calculate a powered sample size. Since then new evidence spe-
ciﬁc to the UK population has been published that would lead us to
revisit those original considerations. This evidence revises esti-
mates about the structural validity of the TFI and its responsiveness
(Fackrell et al., 2016, 2018). Moreover, a global consensus across
different stakeholder groups involving patients, healthcare pro-
fessionals, clinical researchers and representatives from the phar-
maceutical industry has recently made a recommendation for
tinnitus intrusiveness to be the common standard that reﬂects the
impact of tinnitus and for this construct to be assessed in every
pharmaceutical trial of subjective tinnitus (Hall et al., 2018a). In this
study, tinnitus intrusiveness was deﬁned as Noticing the sound of
tinnitus is there and it is invading your life or your personal space.
Further research is warranted to determine whether there are any
available instruments that adequately measure this particular
deﬁnition of tinnitus intrusiveness.
Tinnitus loudness is the most commonly assessed perceptual
attribute of tinnitus yet there is no gold standard for estimating it
(Hall et al., 2016). In the QUIET-1 trial, we chose a loudness
matching procedure based on one that had been developed by
expert healthcare practitioners (Vernon and Meikle, 1981). Never-
theless, the data gathered during the QUIET-1 trial have enabled us
to conclude that this tinnitus loudness matching test performs sub-
optimally on psychometric criteria for reliability and validity
compared to a simple self-rating tool using a Numerical Rating
Scale (Hall et al., 2017). But single questions about loudness are not
without their own limitations as they seem to be interpreted by
patients as synonymous with functional impacts.
In conclusion, despite attempts to design a trial in patients with
subjective tinnitus who might be most sensitive to drug treatment,
the study failed to detect superiority of AUT00063 and met criteria
for futility at the interim analysis. While we are not saying that
futility was attributable to the choice of outcome measures, it is
likely that the primary and secondary tinnitus outcomes were not
the most sensitive to detecting tinnitus-related changes due to the
drug treatment (see also Glait et al., 2018). Again, further research is
warranted to identify instruments that are most sensitive to
assessing change associated with taking a drug for tinnitus. This
may be a speciﬁc instrument for assessing a narrowly deﬁned
construct that is currently measured by a single question or a
subscale or a larger questionnaire.
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